United Kingdom childhood Acute Lymphoblastic Leukaemia Randomised Trial 2003

Conditions

Leukaemia Cancer Lymphoid leukaemia

Rachael Hough, Sabrina Sandhu, Maria Khan, Anthony Moran, Richard Feltbower et al. (10 authors)

BMJ Open2017-10-0126 citations

10.1136/bmjopen-2017-017052

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R.

2014-06-09228 citations

10.1016/s1470-2045(14)70243-8

David O’Connor, Jessica Bate, Rachel Wade, Rachel Clack, Sunita Dhir et al. (9 authors)

Blood2014-06-06246 citations

10.1182/blood-2014-03-560847

IGH@ translocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia

SJ Jeffries, Lisa Jones, Christine J. Harrison, Lisa J. Russell

Haematologica2014-05-0921 citations

10.3324/haematol.2014.103820

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S.

2013-02-07369 citations

10.1016/s1470-2045(12)70600-9

Interventions

MRD high risk group randomised to standard versus intensified therapy MRD low risk group randomised to standard versus reduced therapy Total duration of treatment was

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 1 - 18 years with ALL As of 12/02/2010, young adults up to their 25th birthday are also eligible for this trial.

Exclusion criteria

Exclusion criteria: 1. Mature B ALL 2. Infant ALL (aged less than 1 year) 3. Philadelphia positive ALL

Design outcomes

Primary

Measure	Time frame
Event-free survival, measured at 5 years	—

Secondary

Measure	Time frame
1. Survival, measured at 5 years 2. Quality of life, measured at week 1, week 4, start of maintenance treatment, 18 months, end of treatment 3. Complete response (CR) rate measured at 4 weeks	—

Countries

United Kingdom

Outcome results

None listed